Clinical Trials Browser

Phase 2 × Glioblastoma × tremelimumab × Clear all

NCT02794883 2022-04-18

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Phase 2 Completed

36 enrolled 13 charts

Glioblastoma, Glioma